Skip to content

Study · Randomized controlled trial · 2015

13 results

One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.

Gough SC, Bode BW, Woo VC, Rodbard HW, Linjawi S, Zacho M, Reiter PD, Buse JB

Diabetes, obesity & metabolism1 Jul 2015Cited by 97 (Europe PMC)

PMID25980900 (opens in a new tab)PMCIDPMC4744775 (opens in a new tab)DOI10.1111/dom.12498 (opens in a new tab)PepBankPUB-25980900
Read at sourcePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study13

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In insulin-naive adults with type 2 diabetes, liraglutide alone reduced HbA1c from baseline by 1.21% at 52 weeks.

    In plain wordsIn adults with type 2 diabetes, liraglutide alone lowered HbA1c by 1.21 percentage points over 52 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change at 52 weeks, liraglutide alone
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.21%
    liraglutide alone

    Source sentences

    Summary
    The mean glycated haemoglobin (HbA1c) concentration at 52 weeks was reduced from baseline by 1.84% (20.2 mmol/mol) for the IDegLira group, 1.40% (15.3 mmol/mol) for the insulin degludec group and 1.21% (13.2 mmol/mol) for the liraglutide group.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In insulin-naive adults with type 2 diabetes, 57% of patients on liraglutide alone achieved an HbA1c below 7%.

    In plain wordsIn adults with type 2 diabetes, 57% of those on liraglutide alone reached an HbA1c below 7%.

    Peptide
    Liraglutide
    Outcome
    Not applicableHbA1c below 7% at 52 weeks, liraglutide alone
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Proportion with HbA1c <7%
    57%
    liraglutide alone

    Source sentences

    Summary
    Of the patients on IDegLira, 78% achieved an HbA1c of <7% (53 mmol/mol) versus 63% of the patients on insulin degludec and 57% of those on liraglutide.
    1 context sentence
    Summary · context
    Insulin-naïve adults with type 2 diabetes randomized to once-daily IDegLira, insulin degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In insulin-naive adults with type 2 diabetes, mean fasting plasma glucose at the end of the trial with liraglutide alone was 7.3 mmol/l.

    In plain wordsIn adults with type 2 diabetes, fasting glucose at the end of the trial with liraglutide alone averaged 7.3 mmol/l.

    Peptide
    Liraglutide
    Outcome
    Not applicableFasting plasma glucose at end of trial, liraglutide alone
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Fasting plasma glucose
    7.3 mmol/l
    liraglutide alone

    Source sentences

    Summary
    The mean fasting plasma glucose concentration at the end of the trial was similar for IDegLira (5.7 mmol/l) and insulin degludec (6.0 mmol/l), but higher for liraglutide (7.3 mmol/l).
    1 context sentence
    Summary · context
    Insulin-naïve adults with type 2 diabetes randomized to once-daily IDegLira, insulin degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In insulin-naive adults with type 2 diabetes, HbA1c fell by 1.84% with IDegLira and by 1.40% with insulin degludec alone at 52 weeks.

    In plain wordsIn adults with type 2 diabetes, HbA1c fell more with the insulin and liraglutide combination (1.84%) than with insulin degludec alone (1.40%).

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change at 52 weeks, IDegLira vs insulin degludec
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.84%
    IDegLira
    HbA1c change
    −1.4%
    insulin degludec

    Source sentences

    Summary
    The mean glycated haemoglobin (HbA1c) concentration at 52 weeks was reduced from baseline by 1.84% (20.2 mmol/mol) for the IDegLira group, 1.40% (15.3 mmol/mol) for the insulin degludec group and 1.21% (13.2 mmol/mol) for the liraglutide group.
    1 context sentence
    Summary · context
    Insulin-naïve adults with type 2 diabetes randomized to once-daily IDegLira, insulin degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In insulin-naive adults with type 2 diabetes, 78% of patients on IDegLira achieved an HbA1c below 7%, versus 63% on insulin degludec.

    In plain wordsIn adults with type 2 diabetes, more people reached an HbA1c below 7% with the combination (78%) than with insulin degludec alone (63%).

    Peptide
    Liraglutide
    Outcome
    IncreaseHbA1c below 7%, IDegLira vs insulin degludec
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Proportion with HbA1c <7%
    78%
    IDegLira
    Proportion with HbA1c <7%
    63%
    insulin degludec

    Source sentences

    Summary
    Of the patients on IDegLira, 78% achieved an HbA1c of <7% (53 mmol/mol) versus 63% of the patients on insulin degludec
    1 context sentence
    Summary · context
    Insulin-naïve adults with type 2 diabetes randomized to once-daily IDegLira, insulin degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In insulin-naive adults with type 2 diabetes, end-of-trial fasting plasma glucose was similar with IDegLira (5.7 mmol/l) and insulin degludec (6.0 mmol/l).

    In plain wordsIn adults with type 2 diabetes, fasting glucose at the end of the trial was similar with the combination and with insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    No significant changeFasting plasma glucose, IDegLira vs insulin degludec
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Fasting plasma glucose
    5.7 mmol/l
    IDegLira
    Fasting plasma glucose
    6 mmol/l
    insulin degludec

    Source sentences

    Summary
    The mean fasting plasma glucose concentration at the end of the trial was similar for IDegLira (5.7 mmol/l) and insulin degludec (6.0 mmol/l)
    1 context sentence
    Summary · context
    Insulin-naïve adults with type 2 diabetes randomized to once-daily IDegLira, insulin degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In insulin-naive adults with type 2 diabetes, the daily insulin dose at 52 weeks was 37% lower with IDegLira (39 units) than with insulin degludec (62 units).

    In plain wordsIn adults with type 2 diabetes, the combination needed a lower daily insulin dose than insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseDaily insulin dose at 52 weeks, IDegLira vs insulin degludec
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Daily insulin dose
    39 units
    IDegLira
    Daily insulin dose
    62 units
    insulin degludec

    Source sentences

    Summary
    At 52 weeks, the daily insulin dose was 37% lower with IDegLira (39 units) than with insulin degludec (62 units).
    1 context sentence
    Summary · context
    Insulin-naïve adults with type 2 diabetes randomized to once-daily IDegLira, insulin degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In insulin-naive adults with type 2 diabetes, IDegLira produced a significantly greater decrease in body weight than insulin degludec.

    In plain wordsIn adults with type 2 diabetes, the combination led to more weight loss than insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight, IDegLira vs insulin degludec
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference in body weight
    −2.8 kg
    IDegLira vs insulin degludec

    Source sentences

    Summary
    IDegLira was associated with a significantly greater decrease in body weight (estimated treatment difference, -2.80 kg, p < 0.0001)
    1 context sentence
    Summary · context
    Insulin-naïve adults with type 2 diabetes randomized to once-daily IDegLira, insulin degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial.
  9. 09HumanRandomized controlled trialSafety outcome

    In insulin-naive adults with type 2 diabetes, the hypoglycaemia rate was 37% lower with IDegLira than with insulin degludec.

    In plain wordsIn adults with type 2 diabetes, low blood sugar happened less often with the combination than with insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseHypoglycaemia rate, IDegLira vs insulin degludec
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    Reduction in hypoglycaemia rate
    37%
    IDegLira vs insulin degludec

    Source sentences

    Summary
    a 37% lower rate of hypoglycaemia compared with insulin degludec
    1 context sentence
    Summary · context
    Insulin-naïve adults with type 2 diabetes randomized to once-daily IDegLira, insulin degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 10HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In insulin-naive adults with type 2 diabetes, HbA1c fell by 1.84% with the fixed combination IDegLira and by 1.21% with liraglutide alone at 52 weeks.

    In plain wordsIn adults with type 2 diabetes, HbA1c fell more with the insulin and liraglutide combination (1.84%) than with liraglutide alone (1.21%).

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change at 52 weeks, IDegLira vs liraglutide
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c change
    −1.84%
    IDegLira
    HbA1c change
    −1.21%
    liraglutide

    Source sentences

    Summary
    The mean glycated haemoglobin (HbA1c) concentration at 52 weeks was reduced from baseline by 1.84% (20.2 mmol/mol) for the IDegLira group, 1.40% (15.3 mmol/mol) for the insulin degludec group and 1.21% (13.2 mmol/mol) for the liraglutide group.
    1 context sentence
    Summary · context
    Insulin-naïve adults with type 2 diabetes randomized to once-daily IDegLira, insulin degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 11HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In insulin-naive adults with type 2 diabetes, 78% of patients on IDegLira achieved an HbA1c below 7%, versus 57% on liraglutide.

    In plain wordsIn adults with type 2 diabetes, more people reached an HbA1c below 7% with the combination (78%) than with liraglutide alone (57%).

    Peptide
    Liraglutide
    Outcome
    IncreaseHbA1c below 7%, IDegLira vs liraglutide
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Proportion with HbA1c <7%
    78%
    IDegLira
    Proportion with HbA1c <7%
    57%
    liraglutide

    Source sentences

    Summary
    Of the patients on IDegLira, 78% achieved an HbA1c of <7% (53 mmol/mol) versus 63% of the patients on insulin degludec and 57% of those on liraglutide.
    1 context sentence
    Summary · context
    Insulin-naïve adults with type 2 diabetes randomized to once-daily IDegLira, insulin degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 12HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In insulin-naive adults with type 2 diabetes, end-of-trial fasting plasma glucose was lower with IDegLira (5.7 mmol/l) than with liraglutide (7.3 mmol/l).

    In plain wordsIn adults with type 2 diabetes, fasting glucose at the end of the trial was lower with the combination than with liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose, IDegLira vs liraglutide
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Fasting plasma glucose
    5.7 mmol/l
    IDegLira
    Fasting plasma glucose
    7.3 mmol/l
    liraglutide

    Source sentences

    Summary
    The mean fasting plasma glucose concentration at the end of the trial was similar for IDegLira (5.7 mmol/l) and insulin degludec (6.0 mmol/l), but higher for liraglutide (7.3 mmol/l).
    1 context sentence
    Summary · context
    Insulin-naïve adults with type 2 diabetes randomized to once-daily IDegLira, insulin degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 13HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In insulin-naive adults with type 2 diabetes, all treatments were well tolerated and no new adverse events or tolerability issues were seen for IDegLira.

    In plain wordsIn adults with type 2 diabetes, the combination and its parts were well tolerated, with no new safety issues seen.

    Peptide
    Liraglutide
    Outcome
    No significant changeOverall tolerability, all treatments
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Overall, all treatments were well tolerated and no new adverse events or tolerability issues were observed for IDegLira.
    1 context sentence
    Summary · context
    Insulin-naïve adults with type 2 diabetes randomized to once-daily IDegLira, insulin degludec or liraglutide, in addition to metformin ± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01336023

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 1,66323 May 2011 to 22 Nov 2012

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 19 Feb 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.